Design Therapeutics Inc (DSGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $670.46M
Last updated: Nov 17, 2026 at 11:03 AM ET
Design Therapeutics Inc (DSGN) Stock Forecast
Analysts expect Design Therapeutics (DSGN) to earn -$1.34 per share in the fiscal year ending Dec 31, 2026. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.34
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.56
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.34 | -$1.65 to -$1.26 | 7 |
| Dec 31, 2027 | -$1.56 | -$2.01 to -$1.15 | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.40 for the quarter ending Dec 31, 2026 to -$0.35 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.40 | -$0.61 to -$0.30 | 10 |
| Mar 31, 2027 | -$0.35 | -$0.40 to -$0.29 | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.36.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.34 | -$1.35 | -$1.35 | -$1.36 | -$1.36 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.56 | -$1.62 | -$1.62 | -$1.59 | -$1.59 | N/A |
| Quarter ending Mar 31, 2027 | -$0.35 | -$0.36 | -$0.36 | -$0.35 | -$0.35 | N/A |
Frequently Asked Questions About DSGN
What is the DSGN stock forecast?
Consensus analyst estimates put Design Therapeutics's EPS at -$1.34 for the fiscal year ending Dec 31, 2026. The consensus rating from 8 analysts is Buy.
How do analysts rate DSGN stock?
Of 8 analysts covering Design Therapeutics, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DSGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.34, with estimates from -$1.65 to -$1.26 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.56, with estimates from -$2.01 to -$1.15 from 8 analysts.
How many analysts cover DSGN?
8 analysts rate Design Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DSGN pages: Overview, Earnings, Forecast, Financials, Competitors